ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Macarulla Mercade, T.; Javle, M.; Kelley, R. K.; Lubner, S.; Adeva, J.; Cleary, J. M.; Catenacci, D. V.; Borad, M. J.; Bridgewater, J. A.; Harris, W. P.; Murphy, A. G.; Oh, D. Y.; Whisenant, J.; Wu, B.; Jiang, L.; Gliser, C.; Pandya, S. S.; Valle, J. W.; Zhu, A. X. |
| Abstract Title: | ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz394.027 |
| Language: | English |
| ACCESSION: | WOS:000491295500134 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz394.027 |
| Notes: | Meeting Abstract: LBA10_PR -- Appears on pages v872-v873 of the abstract book -- Source: Wos |
